Code of Federal Regulations: Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and IndexDivision of the Federal Register, the National Archives, 1998 Special edition of the Federal Register, containing a codification of documents of general applicability and future effect ... with ancillaries. |
No grāmatas satura
1.–5. rezultāts no 100.
8. lappuse
Containing a Codification of Documents of General Applicability and Future ... products for oral use ; condi- tions for marketing . 310.501 Patient package ... products in plastic containers . 310.515 Patient package inserts for estro ...
Containing a Codification of Documents of General Applicability and Future ... products for oral use ; condi- tions for marketing . 310.501 Patient package ... products in plastic containers . 310.515 Patient package inserts for estro ...
25. lappuse
Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and Index. of all digoxin products for oral use . The Commissioner is of the opinion that digoxin products for ...
Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and Index. of all digoxin products for oral use . The Commissioner is of the opinion that digoxin products for ...
33. lappuse
... products requires that patients be fully informed of the benefits and the risks involved in their use . An oral contraceptive drug prod- uct that does not comply with the re- quirements of this section is mis- branded under section 502 ...
... products requires that patients be fully informed of the benefits and the risks involved in their use . An oral contraceptive drug prod- uct that does not comply with the re- quirements of this section is mis- branded under section 502 ...
34. lappuse
Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and Index. ( 13 ) The following information about the drug product and the patient pack- age insert : ( i ) The ...
Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and Index. ( 13 ) The following information about the drug product and the patient pack- age insert : ( i ) The ...
38. lappuse
... products contain- ing estrogens requires that patients be fully informed of the benefits and risks involved in the use of these drugs . Ac- cordingly , except as provided in para- graph ( e ) of this section , each estrogen drug product ...
... products contain- ing estrogens requires that patients be fully informed of the benefits and risks involved in the use of these drugs . Ac- cordingly , except as provided in para- graph ( e ) of this section , each estrogen drug product ...
Saturs
279 | |
285 | |
290 | |
299 | |
310 | |
331 | |
339 | |
340 | |
223 | |
236 | |
238 | |
239 | |
240 | |
256 | |
257 | |
262 | |
263 | |
265 | |
270 | |
275 | |
351 | |
483 | |
588 | |
593 | |
696 | |
699 | |
761 | |
826 | |
865 | |
890 | |
911 | |
949 | |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
abbre abbreviated application abbreviated new drug acid active ingredient adverse drug experience agency amended antibiotic application or abbreviated bacitracin bioavailability bioequivalence cation Center for Drug certification chapter clinical hold clinical investigation conducted control number copy Cosmetic Act digoxin dosage form dose Drug Administration drug application Drug Evaluation drug prod drug product Drug products containing drug substance Evaluation and Research Federal Food Food and Drug graph gredients hearing hydrochloride identified information requirements ap insulin intended inves investigational new drug labeling manufacturer marketing meet ment milligrams milliliters misbranded neomycin notice oral dosage orphan drug OTC drug product package paragraph percent person plication polymyxin proposed protocol recognized as safe reference listed drug request safe and effective safety section 502 Sodium sponsor statement submission Subpart sulfate tained tigational tion tive treatment treatment IND vestigational viated warning